Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin

NEW YORK, April 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Regeneron Pharmaceuticals, Inc. Analyst Notes 

On April 1, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron), together with Sanofi, announced that the Phase 2 study with alirocumab, an antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) yielded positive results after it demonstrated a bad cholesterol percentage reduction in patients randomized to receive one of three doses of the said antibody every other week combined with statin therapy, as compared with patients receiving placebo. According to the Company, in week 12, the mean percentage reduction in lipoprotein-cholesterol (LDL-C) receiving alirocumab in 50mg, 75mg, and 150mg doses every other week was 55%, 62%, and 72%, respectively, compared with 3% mean reduction rate in the placebo group. Commenting on the results, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and Laboratories President, Regeneron, said, "Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins. The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients." The full analyst notes on Regeneron Pharmaceuticals, Inc. will be available to download free of charge at:

http://www.AnalystsReview.com/04112014/REGN/report.pdf

--

Questcor Pharmaceuticals, Inc. Analyst Notes 

On March 20, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it is contributing $175,000 to Child Neurology Society (CNS) and Child Neurology Foundation (CNF) to fund the Philip R. Dodge Young Investigator Award, totalling the Company's commitment to the Dodge award to $250,000. Steve Cartt, CEO, Questcor, said, "Questcor's support of the child neurology community is unwavering and we are very pleased to support the Philip R. Dodge Young Investigator Award. Supporting this cornerstone program of the Child Neurology Society will help encourage young scientists to focus their research efforts on initiatives to advance the understanding and treatment of pediatric neurological disorders. Our hope is that these efforts will help pave the way for new and more effective treatments for the many children impacted by these disorders." The full analyst notes on Questcor Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/QCOR/report.pdf

--

Jazz Pharmaceuticals plc Analyst Notes 

On March 31, 2014, Jazz Pharmaceuticals plc (Jazz), together with Gentium S.p.A., announced the European commercial launching of Defitelio (defibrotide), the first licensed product designed to treat sever hepatic veno-occlusive disease (severe VOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy. According to the Company, severe VOD is a complex and unpredictable disease affecting in over 80% of European patients. Jazz stated that the efficacy of Defitelio to treat sVOD in HSCT patients resulted from a successful phase 3 trial that provided a significant increase of 52% survival rates among patients treated for 100 days compared with patients in the historical control group. The Company informed that Defitelio will be launched in 27 additional European countries starting in 2014 until next year. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:

http://www.AnalystsReview.com/04112014/JAZZ/report.pdf

--

Ariad Pharmaceuticals, Inc. Analyst Notes 

On March 24, 2014, Ariad Pharmaceuticals, Inc. (Ariad) announced the initiation of the pivotal Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ariad informed that ALK in Lung Cancer Trial of AP26113 (ALTA) is designed to determine the safety and efficacy of AP26113 in patients who tested positive for anaplastic lymphoma kinase (ALK+) oncogene. According to the Company, the ALTA trial's primary goal is to achieve an objective response rate (ORR) measured by RECIST criteria, while recording time to response, duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability comes secondary. Ariad added that full patient enrolment is expected in Q3 2015 and the Company expects to report first data from the trial in during the medical meeting in 2015. The full analyst notes on Ariad Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/ARIA/report.pdf

--

BioMarin Pharmaceutical Inc. Analyst Notes 

On March 21, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Dennis J. Slamon, M.D. Ph.D., Clinical/Translational Research Director Revlon /UCLA Women's Cancer Research Program Director, to the Company's Board of Directors. According to the Company, Dr. Slamon won nearly two dozen national and international research awards honoring his scientific endeavors, and has mostly changed the way cancer is treated. Commenting on the appointment, Jean-Jacques Bienaimé, CEO, BioMarin, said, "I am delighted that Dr. Slamon will be joining BioMarin's board. His experience in translating discovery into medicines is aligned with our mission to treat patients with unmet medical needs based on a specific knowledge of the molecular basis of their disease. As BioMarin builds its pipeline of early and late stage therapies, Dr. Slamon's support will help us achieve success in the clinic." The full analyst notes on BioMarin Pharmaceutical Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/BMRN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review